ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO ##### Up next ![AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact](https://i0.wp.com/r2.thailandbusinessnews.net/2025/07/2025_Asia_WOP__JPEG.jpg?resize=200%2C110&ssl=1 "AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact") [](https://thailandbusinessnews.net/press-release/abbvies-10th-week-of-possibilities-unites-employees-across-asia-for-community-impact/) ###### [AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact](https://thailandbusinessnews.net/press-release/abbvies-10th-week-of-possibilities-unites-employees-across-asia-for-community-impact/) Published on 16 July 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) ![](https://mma.prnasia.com/media2/2516404/ArkBio_Logo.jpg?p=medium600 "logo") SHANGHAI, July 16, 2025 /PRNewswire/ — In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included in the PADO-RSV priority list. Ziresovir, developed by Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), is the first and only RSV antiviral drug to be included in the list. This is the first time WHO has included an anti-RSV drug developed from China in the paediatric drug optimization priority list. Filling a Global Gap: Ziresovir Leads RSV Antiviral Development RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing approximately 33 million cases of LRTIs, 3.6 million hospitalizations, and 101,400 deaths annually, with 97% of deaths occurring in low- and middle-income countries (LMICs). Despite the severe threat, current specific treatment options for RSV are extremely limited, and there is a clinical urgent need for safe, effective, and child-appropriate innovative drugs. The "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV)" project initiated by WHO/GAP-f aims to systematically review the global R&D pipeline, clarify R&D priorities, and promote the development and accessibility of RSV prevention and treatment tools more suitable for the paediatric population. With its clear clinical value, child-friendly design, and good safety profile, ziresovir becomes the only product in the antiviral drug category selected for the PADO-RSV priority list, demonstrating its huge potential in the paediatric RSV treatment globally. WHO pointed out in the report that ziresovir’s research results are of great significance to the global RSV treatment field and recommended conducting diverse clinical studies in broader populations to further verify its applicability and effectiveness. ArkBio will actively respond to WHO’s advice with a plan to expand ziresovir’s clinical development in other countries and regions. By collaborating with international scientific institutions and public health organizations, ArkBio aims to rapidly advance the drug’s global registration and accessibility. Simultaneously, ArkBio is deeply aware of the importance of global public health, particularly concerned about the challenges faced by low- and middle-income countries. The company will formulate drug accessibility plans specifically for these countries to ensure ziresovir can be supplied at reasonable prices globally wherever it is needed, contributing to the prevention and treatment of RSV infection. "ArkBio has a mission to ‘help patients inspire and thrive’", Dr. Jim Wu, CEO of ArkBio, stated. "The inclusion of ziresovir in the WHO PADO-RSV priority list is not only an affirmation of the years of effort by ArkBio scientists, but also an inspiration for our corporate mission. The recognition of ziresovir would allow us to expedite its global development and realize the potential on the global stage. We will ensure the innovation can not only benefit patients in China but the very needed patients worldwide. This is not just our goal but our social responsibility. ArkBio will strive to contribute more to address global public health issues." About GAP-f GAP-f stands for the Global Accelerator for Paediatric Formulations Network. Hosted by WHO, it operates throughout the drug development lifecycle to accelerate the research, development, and dissemination of optimized pediatric formulations. Identifying priorities is the first step toward a targeted R&D approach. Establishing a priority list of the most urgently needed pediatric formulations is crucial, as it helps focus the efforts and resources of researchers and suppliers on specific dosage forms and formulations that address children’s most critical needs. About PADO PADO stands for Paediatric Drug Optimization. It is a WHO’s legally binding international priority (based on WHA69.20 resolution) that accelerates the development of high-demand pediatric drugs by building consensus among regulators, funders, and manufacturers. It aims to identify priority products for R&D and define their ideal characteristics. It has been successfully implemented in areas including human immunodeficiency virus (HIV), hepatitis C, tuberculosis, COVID-19, antibiotics, neglected tropical diseases, and childhood cancers. These initiatives demonstrate that, against the backdrop of a fragmented and small pediatric drug market, such efforts hold potential and deliver tangible impacts in accelerating access to optimized formulations. About Ziresovir Ziresovir is a novel small-molecule RSV fusion (F) protein inhibitor. It binds to the pre-F protein conformation of the virus and prevents viral entry into human cells. Ziresovir can also suppress RSV viral transmission by blocking cell-to-cell fusion through the formation of "syncytia", a characteristic event of RSV infection of host cells. It is the first oral anti-RSV drug that has completed a phase 3 pivotal clinical study with positive results. The phase 3 results have been published in The New England Journal of Medicine and The Lancet Child & Adolescent Health. Ziresovir has received Breakthrough Therapy designation by the National Medical Products Administration (NMPA) of China. About ArkBio ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and Azstarys (AK0901), an FDA-approved ADHD therapeutic drug. ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information, please visit: [www.arkbiosciences.com](https://www.arkbiosciences.com/)Investor Inquiries: [Source link ](https://www.prnasia.com/story/archive/4730400_AE30400_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/acm-biolabs-reports-favorable-safety-signals-and-early-pharmacodynamics-from-intramuscular-administration-of-acm-cpg-in-patients-with-advanced-solid-tumors/) ## ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors SINGAPORE, Oct. 22, 2025 /PRNewswire/ — ACM Biolabs, a clinical-stage biotechnology company developing next-generation… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - October 22, 2025 [](https://thailandbusinessnews.net/press-release/unlock-vietnams-market-join-ite-hcmc-2025-hosted-buyer-program-today/) ![Unlock Vietnam's Market: Join ITE HCMC 2025 Hosted Buyer Program Today!](https://i0.wp.com/r2.thailandbusinessnews.net/2025/07/Hi_nh_tcbc.jpg?resize=260%2C140&ssl=1 "Unlock Vietnam's Market: Join ITE HCMC 2025 Hosted Buyer Program Today!") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## Unlock Vietnam's Market: Join ITE HCMC 2025 Hosted Buyer Program Today! HO CHI MINH CITY, Vietnam, July 1, 2025 /PRNewswire/ — The 19th… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - July 1, 2025 [](https://thailandbusinessnews.net/press-release/sanya-2026-ticketing-system-launched-118000-discounted-tickets-on-sale-globally/) ![Sanya 2026 Ticketing System Launched: 118,000 Discounted Tickets on Sale Globally](https://i0.wp.com/mma.prnasia.com/media2/2943276/The_6th_Asian_Beach_Games_Sanya_2026_30_day_countdown_press.jpg?resize=260%2C140&ssl=1 "Sanya 2026 Ticketing System Launched: 118,000 Discounted Tickets on Sale Globally") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## Sanya 2026 Ticketing System Launched: 118,000 Discounted Tickets on Sale Globally SANYA, China, March 26, 2026 /PRNewswire/ — On March 23, at the… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - March 26, 2026 ##### Most Read - [![Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/finloop-raises-over-us10-million-in-series-a-financing-welcomes-hsbc-as-one-of-its-strategic-investors-and-launches-its-corporate-service-finterprise/ "Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"") [Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"](https://thailandbusinessnews.net/press-release/finloop-raises-over-us10-million-in-series-a-financing-welcomes-hsbc-as-one-of-its-strategic-investors-and-launches-its-corporate-service-finterprise/ "Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"") - [![Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") [Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") - [![Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") [Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") - [![Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") [Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") - [![GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/gccl-and-medicover-integrated-clinical-services-announce-strategic-collaboration-to-strengthen-multinational-clinical-trial-services/ "GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services") [GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services](https://thailandbusinessnews.net/press-release/gccl-and-medicover-integrated-clinical-services-announce-strategic-collaboration-to-strengthen-multinational-clinical-trial-services/ "GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services") - [![600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/600-clubs-strong-inspire-brands-asia-continues-regional-expansion-affirms-vision-for-1000-by-2028/ "600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028") [600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028](https://thailandbusinessnews.net/press-release/600-clubs-strong-inspire-brands-asia-continues-regional-expansion-affirms-vision-for-1000-by-2028/ "600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/cellebrite-expands-global-digital-community-the-101-for-digital-forensics-and-investigative-professionals/) ![Cellebrite Expands Global Digital Community, 'The 101', for Digital Forensics and Investigative Professionals](https://i0.wp.com/mmx.prnasia.com/media/MS1775952/Cellebrite-Logo.jpg?resize=260%2C140&ssl=1 "Cellebrite Expands Global Digital Community, 'The 101', for Digital Forensics and Investigative Professionals") ## Cellebrite Expands Global Digital Community, 'The 101', for Digital Forensics and Investigative Professionals Purpose-built platform connects customers worldwide with peers and Cellebrite experts… [](https://thailandbusinessnews.net/press-release/eightco-holdings-nasdaq-orbs-reports-total-holdings-of-approximately-380-million-includes-openai-beast-industries-more-than-16000-eth-and-nearly-302-million-wld-tokens-2/) ![Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately 0 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens](https://i0.wp.com/mmx.prnasia.com/media/MS695659/Eightco-Logo.jpg?resize=260%2C140&ssl=1 "Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately 0 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens") ## Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $380 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens Eightco treasury composition as of September 16, 2026: $90M OpenAI equity (indirect),… [](https://thailandbusinessnews.net/press-release/theres-no-one-size-fits-all-for-treating-older-adults-with-cancer-according-to-new-nccn-patient-resource/) ## There's No One-Size-Fits-All for Treating Older Adults with Cancer, According to New NCCN Patient Resource New guideline for patients and caregivers explains the importance of assessments to… [](https://thailandbusinessnews.net/press-release/loccitane-group-achieves-a-new-milestone-in-its-b-corp-certification-journey/) ![L'OCCITANE Group achieves a new milestone in its B Corp™ certification journey](https://i0.wp.com/mmx.prnasia.com/media/MS1989037/Key_Visual_Vertical_2_No_Border-T.jpg?resize=260%2C140&ssl=1 "L'OCCITANE Group achieves a new milestone in its B Corp™ certification journey") ## L'OCCITANE Group achieves a new milestone in its B Corp™ certification journey Progress is measured not only by what is achieved, but by the…